Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure (Q43191785)

15 November 2017

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure (English)

1 reference

15 November 2017

0 references

1 reference

3

1 reference

15 November 2017

4

1 reference

15 November 2017

11

1 reference

Torsten Toftegaard Nielsen

15 November 2017

Henrik Wiggers

12

0 references

Hans Eiskjaer

object named as

Hans Eiskjaer

series ordinal

10

0 references

series ordinal

9

object named as

Torsten Toftegaard Nielsen

1 reference

15 November 2017

6

Roni Nielsen

1 reference

15 November 2017

2

Helene Nørrelund

1 reference

15 November 2017

1

Mads Halbirk

1 reference

15 November 2017

5

Ole Schmitz

1 reference

PubMed ID

20081109

15 November 2017

Jens Erik Nielsen-Kudsk

series ordinal

7

object named as

Jens Erik Nielsen-Kudsk

1 reference

15 November 2017

8

Søren Steen Nielsen

1 reference

15 November 2017

15 January 2010

1 reference

American Journal of Physiology Heart and Circulatory Physiology

15 November 2017

1 reference

15 November 2017

298

1 reference

15 November 2017

H1096-102

1 reference

15 November 2017

3

1 reference

Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation.

15 November 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Free fatty acid kinetics and oxidation in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Myocardial substrate metabolism in the normal and failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Cardiac metabolism as a target for the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00930.2009

10.1152/AJPHEART.00930.2009

21 January 2018

Identifiers

DOI

1 reference

15 November 2017

1 reference

PubMed ID

20081109